ASP1 Antibody

What is rOv-ASP-1 and how does it function as an antibody adjuvant?

rOv-ASP-1 is a recombinant protein derived from the helminth parasite Onchocerca volvulus, specifically its activation-associated secreted protein-1. This protein functions as a potent adjuvant that enhances immune responses to co-administered antigens in vaccines.

The adjuvant properties of rOv-ASP-1 exceed the efficacy of traditional adjuvants like alum or MPL+TDM in stimulating antibody responses. When used with antigens such as ovalbumin (OVA), it induces higher endpoint total IgG, IgG1, and IgG2a antibody titers compared to conventional adjuvants . What makes rOv-ASP-1 particularly interesting is that it induces a mixed Th1/Th2 antibody response profile while predominantly stimulating Th1-type cytokines from spleen cells .

The mechanism involves activating human monocyte-derived dendritic cells to secrete cytokines and mature them to induce activation of naïve T cells . Additionally, rOv-ASP-1 promotes chemokine accumulation at injection sites and recruits immune cells such as monocytes, macrophages, and neutrophils, enhancing the activation of CD4+ T cell responses essential for antibody production .

What are Asp1 monoclonal antibodies and their applications in neurological research?

Asp1 monoclonal antibodies refer to antibodies specifically developed to recognize fixative-modified aspartate in tissues. These antibodies serve as valuable tools in neurological research for immunocytochemical staining of central nervous system (CNS) structures.

Research has demonstrated that monoclonal antibodies designated as Asp1, Asp2, and Asp3 have high selectivity for aldehyde-fixed aspartate . In rat CNS studies, these antibodies produce similar staining patterns, highlighting neuronal cell bodies, dendrites, and fibers in various brain regions . The specificity of these antibodies has been rigorously evaluated through enzyme-linked immunoassays (ELISA), examining their reactivity to conjugates of small molecules and their inhibition by free small molecules containing aspartate .

These antibodies enable researchers to identify and map aspartate-containing neurons, which is crucial for understanding neural circuits and neurotransmitter systems. Preliminary data indicate that Asp13 (another variant) produces similar staining patterns in neuronal cell bodies, dendrites, and fibers in various CNS regions .

How does the Asp1 residue contribute to antibody catalytic function?

The Asp1 residue (aspartic acid at position 1) plays a critical role in the catalytic properties of certain antibodies, particularly in developing catalytic antibodies that possess both antigen recognition and degradation capabilities.

Research on catalytic antibodies targeting influenza A virus hemagglutinin has shown that Asp1, working together with Ser92 and His93, creates a catalytic site when properly positioned . In studies where Pro95 was deleted in the CDR-3 region of antibody light chains, these three residues (Asp1, Ser92, and His93) moved closer together, enhancing both catalytic function and immunoreactivity . This modification increased the affinity of the antibody light chains to their antigen approximately 100-fold compared to wild-type light chains .

The precise positioning of Asp1 contributes to creating a functional active site that can cleave specific antigens. Notably, the Pro95-deleted catalytic light chains containing properly positioned Asp1 could suppress influenza virus infection in vitro, whereas the parent antibody and unchanged light chain did not demonstrate this capability .

What is ASP1's role in autoimmune conditions like APS1?

In the context of autoimmune diseases, ASP1 refers to Autoimmune Polyglandular Syndrome type 1 (APS1), a rare inherited autoimmune disorder caused by mutations in both copies of the autoimmune regulator (AIRE) gene.

In APS1, the immune system abnormally recognizes cells in multiple organs and glands as foreign, mounting antibody-based immune attacks against them that result in tissue damage . The condition is clinically defined by at least two of three core features: hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis (CMC) .

Recent research in a case study has shown that early immunosuppressive treatment can normalize some signs of autoimmunity, halt the development of additional autoimmune diseases, and even reverse certain symptoms like total body hair loss . This suggests that interventions targeting the abnormal antibody responses may benefit in managing the condition, though traditionally immunosuppressive therapies have been reserved for life-threatening features of APS1 .

How can researchers optimize rOv-ASP-1 for antigen-sparing in vaccine development?

Optimizing rOv-ASP-1 for antigen-sparing is particularly valuable during pandemics when vaccines cannot be produced in sufficient quantities. Research has demonstrated that rOv-ASP-1 can induce protection with significantly reduced antigen doses.

Studies with the trivalent inactivated influenza vaccine (IIV3) show that rOv-ASP-1 can induce protection with 40-times less IIV3 than standard doses . This substantial antigen-sparing effect operates independently of IIV3-specific Th1/Th2-associated antibody responses and the presence of hemagglutination inhibition (HAI) antibodies, though CD4+ T helper cells are indispensable for protection .

For optimal production and purification, researchers should consider:

• Expression system optimization: Using pET28a/BL21(DE3) with IPTG induction significantly increases yield compared to previous systems like pTrcHis/DH5α .

• Purification protocol: Solubilize inclusion bodies in 1% SDS and purify with Immobilized Metal Affinity Chromatography (IMAC). The purified protein should remain soluble in PBS, pH 7.4 containing 0.1% SDS .

• LPS removal: Treating rOv-ASP-1 with LPS-removing gel enhances its adjuvant properties, with treated rOv-ASP-1 showing better performance in augmenting antibody responses compared to untreated protein .

• Dose optimization: Even reduced amounts of rOv-ASP-1 maintain protective effects when paired with substantially lower antigen doses, allowing researchers to determine minimal effective concentrations .

What cellular and molecular mechanisms underlie rOv-ASP-1's adjuvant effects?

The adjuvant effects of rOv-ASP-1 involve several cellular and molecular mechanisms:

• Chemokine induction: rOv-ASP-1, with or without vaccine antigens, elicits increased levels of various chemokines at the injection site within hours after immunization . These chemokines serve as chemoattractants for immune cells, creating a local inflammatory environment that enhances antigen presentation.

• Immune cell recruitment: The adjuvant significantly induces recruitment of monocytes, macrophages, and neutrophils to the injection site . The recruited monocytes show higher expression of activation marker MHCII on their surface, as well as CXCR3 and CCR2 (receptors for IP-10 and MCP-1, respectively) .

• Dendritic cell activation: rOv-ASP-1 activates and matures human monocyte-derived dendritic cells, inducing them to secrete cytokines and activate naïve T cells . This is crucial for initiating adaptive immune responses.

• Mixed Th1/Th2 response: Unlike many helminth products that typically induce Th2-skewed responses, rOv-ASP-1 induces a balanced Th1/Th2 antibody profile or even a Th1-dominated response depending on the antigen . When used with ovalbumin, it stimulates both IgG1 (Th2-associated) and IgG2a (Th1-associated) antibody responses .

• CD4+ T cell dependency: Protection elicited by rOv-ASP-1-adjuvanted vaccines depends on CD4+ T helper cells, which are essential for generating strong antibody responses .

• MyD88-independent signaling: Interestingly, the protection induced by rOv-ASP-1-adjuvanted vaccines appears to function independently of MyD88 signaling, suggesting it operates through alternative immune activation pathways compared to many other adjuvants .

How can researchers improve monoclonal Asp1 antibody specificity?

Improving the specificity of Asp1 monoclonal antibodies requires rigorous characterization and optimization approaches:

• Comprehensive cross-reactivity testing: Asp1 antibodies should be tested against a wide panel of conjugates and small molecules to identify potential cross-reactivity. Research shows that Asp1 antibodies react with β-Asp-Asp/KLH but not with γ-L-glutamyl-L-glutamate/KLH or γ-aminobutyryl-γ-aminobutyric acid/KLH .

• Inhibition assays with free small molecules: Testing various free small molecules' ability to inhibit antibody binding provides valuable specificity information. Studies demonstrate that Asp1 antibody immunoreactivity can be inhibited by molecules like N-acetyl-Asp, β-Asp-Asp, and Gly-Asp, with different concentration-dependent inhibition profiles .

• Carrier protein selection: The choice of carrier protein (KLH or BSA) and conjugation method (glutaraldehyde-borohydride, acrolein, etc.) significantly impacts antibody specificity. Conjugates containing aspartate effectively inhibit Asp1-3 antibodies at much lower concentrations than conjugates containing other amino acids .

• Subcloning and isotype selection: Subcloning hybridomas by limiting dilution and selecting specific isotypes (IgG1 for Asp1 and Asp2, IgM for Asp3) can improve specificity and reduce batch-to-batch variation .

• Concentration optimization: Determining optimal antibody concentration can maximize signal-to-noise ratio. Generating concentration-dependent inhibition curves helps identify ideal working concentrations .

• Tissue-specific validation: For immunocytochemical applications, validating with appropriate tissue controls is essential to differentiate specific staining from background.

What is the significance of the Asp1 residue in developing catalytic antibodies?

The Asp1 residue plays a crucial role in developing catalytic antibodies with dual functionality for both antigen recognition and degradation:

• Active site formation: Research demonstrates that Asp1, properly positioned with other residues like Ser92 and His93, contributes to forming a catalytic site similar to those in natural enzymes . This catalytic triad enables antibodies to not only bind antigens but also cleave them.

• Enhanced catalytic activity through mutagenesis: Studies show that deleting Pro95 in the CDR-3 region of antibody light chains causes Asp1, Ser92, and His93 to move closer together, creating an optimal configuration for catalytic activity . This structural change enables previously non-catalytic antibodies to cleave antigenic peptides.

• Improved antigen binding: The same structural changes enhancing catalytic activity also significantly improve antigen binding. Pro95-deleted light chains with properly positioned Asp1 exhibit approximately 100-fold higher antigen affinity compared to wild-type light chains .

• Functional antiviral activity: Catalytic antibodies with optimized Asp1 positioning have demonstrated the ability to suppress influenza virus infection in vitro, whereas parent antibodies lacking catalytic activity showed no such effects .

• Efficient therapeutic development: The ability to quickly convert existing monoclonal antibodies into catalytic antibodies by optimizing Asp1 positioning offers a rapid strategy for developing new therapeutic tools . This approach provides a faster alternative to the traditionally time-consuming preparation of catalytic antibodies.

What experimental design is optimal for evaluating rOv-ASP-1 adjuvanticity?

To properly evaluate rOv-ASP-1 adjuvanticity, researchers should implement a comprehensive experimental design that assesses both humoral and cellular immune responses, along with protective efficacy:

• Study groups and controls:

  • Test groups: Antigen + rOv-ASP-1 at various concentrations

  • Positive controls: Antigen + established adjuvants (alum, MPL+TDM)

  • Negative controls: Antigen alone, PBS alone, rOv-ASP-1 alone

• Immunization protocol:

  • Multiple immunization schedules (single vs. prime-boost)

  • Standardized administration route (typically intramuscular)

  • Optimized intervals between immunizations (2-4 weeks)

• Antibody response assessment:

  Parameter	Method	Key Metrics
  Total antibody	ELISA	Endpoint titers
  Isotype profile	Isotype-specific ELISA	IgG1, IgG2a, IgG2b ratios
  Functional antibodies	Neutralization assays, HAI	IC50, HAI titers
  Antibody avidity	Avidity ELISA	Avidity index

• Cellular response evaluation:

  • T cell cytokine profiling (IFN-γ, IL-2, IL-4, IL-5, IL-10) by ELISPOT or flow cytometry

  • T helper cell polarization (Th1/Th2/Th17)

  • CD4+ and CD8+ T cell activation and proliferation analysis

• Antigen-sparing assessment:

  • Test decreasing antigen doses with constant adjuvant concentration

  • Determine minimum protective antigen dose

  • Compare protection between standard dose and reduced doses with adjuvant

• Challenge studies (for relevant models):

  • Pathogen challenge in appropriate animal models

  • Evaluate protection parameters (survival, pathogen burden)

  • Compare protection between adjuvanted groups

• Mechanistic investigations:

  • Chemokine production at injection site

  • Immune cell recruitment and activation analysis

  • Dendritic cell maturation assessment

What validation methods are essential for Asp1 monoclonal antibody specificity?

For rigorous validation of Asp1 monoclonal antibody specificity, researchers should implement a comprehensive set of controls and analytical methods:

• ELISA specificity validation:

  • Test reactivity against conjugates coated on plates

  • Evaluate multiple conjugates to confirm specificity for aspartate-containing compounds

  • Create concentration-dependent inhibition curves with small molecules

  • Compare inhibition profiles of aspartate-containing molecules versus other amino acids

• Immunohistochemical validation:

  • Preabsorption controls: Preincubate antibodies with aspartate conjugates before staining

  • Staining pattern consistency: Compare patterns across brain regions and species

  • Comparison with known neurochemical markers

  • Background controls: Primary antibody omission, non-immune immunoglobulins

• Biochemical characterization:

  • Western blot analysis to confirm molecular weight specificity

  • Dot blot assays with various amino acid conjugates

  • Competition assays with structurally related compounds

  • Isotype determination (IgG1 for Asp1 and Asp2, IgM for Asp3)

• Cross-reactivity assessment:

  Molecule	Relative Reactivity	Concentration for 50% Inhibition
  β-Asp-Asp	High	Low μM range
  N-acetyl-Asp	Moderate	Mid μM range
  Gly-Asp	Low	High μM range
  Glutamate	Very low/none	>1000 μM

• Carrier protein effects:

  • Test antibody reactivity against conjugates made with different carrier proteins

  • Evaluate the impact of conjugation chemistry on epitope recognition

  • Compare glutaraldehyde-borohydride versus acrolein conjugation methods

The validation should confirm that Asp1 antibodies recognize specifically aspartate-containing conjugates while showing minimal cross-reactivity with other amino acids or neurotransmitters.

How can researchers analyze ASP1 antibody data using computational approaches?

Computational approaches offer powerful tools for analyzing ASP1 antibody data across various research contexts:

• Protein structure prediction:

  • AlphaFold 2 has been successfully used to predict protein structures and support wet lab antibody-receptor interaction data

  • These models can visualize how ASP1 proteins interact with antibodies and predict binding interfaces

  • For catalytic antibodies, structure prediction can identify how Asp1 residue modifications affect catalytic site formation

• Ab initio antibody design:

  • Advanced models like AbODE (Ab Initio Antibody Design using Conjoined ODEs) extend graph PDEs to accommodate contextual information and external interactions

  • These approaches can help design antibodies with optimal binding to ASP1-related targets

  • Continuous differential attention mechanisms can capture evolving interactions within antibodies and between antibodies and antigens

• Systems serology computational methods:

  • Techniques that simplify complex molecular interactions between antibodies and targets

  • Pattern recognition algorithms identifying relationships between antibody features and immune responses

  • Visual depiction of patterns found in antibody analysis showing correlations between subjects, receptors, antigens, and antibody structure

• Similarity graphs for antibody classification:

  • Construction of similarity graphs based on misclassification patterns

  • Nodes represent antibodies, edges represent misclassifications

  • Edge weights correspond to misclassification frequency

  • This approach helps identify antibodies with potential biological similarities

What parameters should be measured in catalytic antibody studies involving Asp1 modifications?

When evaluating catalytic antibodies with Asp1 modifications, researchers should implement a multi-parameter assessment approach:

Research has demonstrated that Pro95-deleted light chains exhibit catalytic activity to cleave antigenic peptides from conserved regions of hemagglutinin molecules, with approximately 100-fold increased antigen affinity compared to wild-type . The proper positioning of the Asp1-Ser92-His93 catalytic triad is critical for this enhanced activity.

How should researchers interpret contradictory data in ASP1 antibody studies?

When faced with contradictory data in ASP1 antibody research, implement systematic approaches to resolve discrepancies:

• Methodological standardization:

  • Develop consistent protocols for antibody production and characterization

  • Standardize assay conditions across laboratories

  • Establish reference standards for quantitative comparisons

  • Consider how different experimental conditions might contribute to varying results

• Cross-platform verification:

  • Confirm findings using multiple complementary techniques

  • For binding studies, compare results from ELISA, SPR, and cell-based assays

  • Validate functional effects through both in vitro and in vivo approaches

  • Evaluate whether different detection methods might explain discrepancies

• Experimental context analysis:

  • Systematically investigate how experimental conditions affect outcomes

  • Consider buffer composition, pH, temperature, and incubation times

  • Evaluate the impact of different expression systems and purification methods

  • Assess batch-to-batch variations in antibody or antigen preparations

• Context-specific considerations:

  • For rOv-ASP-1 adjuvant studies: Inconsistent results may stem from variations in protein preparation or endotoxin contamination

  • For Asp1 monoclonal antibodies: Differences in fixation methods or tissue processing can affect epitope accessibility

  • For catalytic antibodies: Subtle structural variations can significantly impact catalytic activity

• Data integration approaches:

  • Develop comprehensive models incorporating all available data

  • Use Bayesian methods to update confidence in hypotheses as new data emerges

  • Create visualization tools highlighting areas of agreement and disagreement

  • Consider whether seemingly contradictory results might be reconciled by additional variables

What are the key challenges in developing effective Asp1-targeted catalytic antibodies?

Developing effective Asp1-targeted catalytic antibodies presents several key challenges that researchers must address:

Recent research has made significant progress in addressing some of these challenges, demonstrating that site-directed mutagenesis (specifically deleting Pro95 in CDR-3 of the light chain) can successfully convert regular monoclonal antibodies into catalytic antibodies with enhanced activity against influenza virus hemagglutinin .

How does rOv-ASP-1's adjuvant efficacy compare across different antigen types?

rOv-ASP-1's adjuvant efficacy varies across different antigen types, with important considerations for research applications: